Carbamazepine Induced Bullous Pemphigoid in a 49 Year Old Male

Brendan Gleason, Lisa Matonti, PharmD, BCPS, Xuejun Alice Wang, MD, Bahar Dasgeb, MD
{"title":"Carbamazepine Induced Bullous Pemphigoid in a 49 Year Old Male","authors":"Brendan Gleason, Lisa Matonti, PharmD, BCPS, Xuejun Alice Wang, MD, Bahar Dasgeb, MD","doi":"10.29046/tmf.022.1.009","DOIUrl":null,"url":null,"abstract":"Bullous pemphigoid is an autoimmune blistering condition mediated by autoantibodies 1 . It is categorized as an uncommon disorder 2-4 , with an estimated incidence of 2.4-21.7 cases per million 2-6 but carries significant morbidity and mortality, warranting clinical awareness and investigation 7,8 . A number of medications have been implicated in the development of bullous pemphigoid including loop diuretics, ace inhibitors, and anti-epileptic drugs. This is a case report of carbamazepine-induced bullous pemphigoid in a 49-year-old male after taking the medication for almost 30 years. Diagnosis of bullous pemphigoid was based on biopsy histology and immunofluorescence, as well as the presence of BP 180 antibody. Clinical features of extensive rash and bullae were present on dermatological exam. Upon discontinuation of carbamazepine and appropriate treatment of bullous pemphigoid, the patient’s condition improved. A thorough analysis of the patient’s history and medications did not reveal any other potential triggers of bullous pemphigoid. The only two previous reports of an association between carbamazepine and bullous pemphigoid are limited by lack of immunologic evidence of diagnosis or the identification of a specific causative agent. To address these limitations, we describe what is to our knowledge, the first reported case of clearly documented association between carbamazepine and bullous pemphigoid.","PeriodicalId":246494,"journal":{"name":"The Medicine Forum","volume":"31 3","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Medicine Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29046/tmf.022.1.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Bullous pemphigoid is an autoimmune blistering condition mediated by autoantibodies 1 . It is categorized as an uncommon disorder 2-4 , with an estimated incidence of 2.4-21.7 cases per million 2-6 but carries significant morbidity and mortality, warranting clinical awareness and investigation 7,8 . A number of medications have been implicated in the development of bullous pemphigoid including loop diuretics, ace inhibitors, and anti-epileptic drugs. This is a case report of carbamazepine-induced bullous pemphigoid in a 49-year-old male after taking the medication for almost 30 years. Diagnosis of bullous pemphigoid was based on biopsy histology and immunofluorescence, as well as the presence of BP 180 antibody. Clinical features of extensive rash and bullae were present on dermatological exam. Upon discontinuation of carbamazepine and appropriate treatment of bullous pemphigoid, the patient’s condition improved. A thorough analysis of the patient’s history and medications did not reveal any other potential triggers of bullous pemphigoid. The only two previous reports of an association between carbamazepine and bullous pemphigoid are limited by lack of immunologic evidence of diagnosis or the identification of a specific causative agent. To address these limitations, we describe what is to our knowledge, the first reported case of clearly documented association between carbamazepine and bullous pemphigoid.
卡马西平致49岁男性大疱性类天疱疮1例
大疱性类天疱疮是一种由自身抗体介导的自身免疫性水泡。它被归类为一种不常见的疾病2-4,估计发病率为每百万2.4-21.7例2-6,但具有显著的发病率和死亡率,需要临床意识和调查7,8。许多药物与大疱性类天疱疮的发展有关,包括环利尿剂、ace抑制剂和抗癫痫药物。这是一个病例报告卡马西平诱导大疱性类天疱疮在49岁的男性服药后近30年。大疱性类天疱疮的诊断是基于活检组织学和免疫荧光,以及BP 180抗体的存在。皮肤科检查表现为广泛的皮疹和大疱。停用卡马西平并适当治疗大疱性类天疱疮后,患者病情好转。对患者病史和药物的彻底分析没有揭示任何其他潜在的大疱性类天疱疮的触发因素。卡马西平与大疱性类天疱疮之间仅有的两份先前的相关报告由于缺乏诊断的免疫学证据或特定病原体的鉴定而受到限制。为了解决这些局限性,我们描述了据我们所知,卡马西平和大疱性类天疱疮之间明确记录的第一个报告病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信